It is crucial that drug toxicity is kept as low as possible to improve the quality of life of patients. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH), Prof. John DiPersio, MD, PhD of Washington University School of Medicine, Washington, WA discusses using MGD006, a dual-affinity re-targeting agent, to target CD123 in patients with acute myeloid leukemia (AML). He provides an overview on the progress of the ongoing Phase I study (NCT02152956) looking at the toxicity of this drug in patients with relapsed AML and high-risk myelodysplastic syndrome.
Bispecific agents: the future of AML and MDS treatment?
